Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada/Division of Neurology, Tel Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv Israel.
Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Mult Scler. 2021 Jun;27(7):1027-1036. doi: 10.1177/1352458520948212. Epub 2020 Aug 11.
Multiple sclerosis (MS) incidence is rising in traditionally low-burden regions, including the Middle East and North Africa (MENA).
Our objective was to evaluate disease characteristics in MS patients of MENA descent (MENA-MS).
MENA-MS patients and age- and sex-matched MS patients of European descent (EUR-MS) were identified through the MS Clinic Registry of St. Michael's Hospital in Toronto, Canada. Disease activity and severity were evaluated by the annualized relapse rate (ARR), magnetic resonance imaging (MRI) activity, change in the Expanded Disability Status Scale (EDSS), progression index (PI), and MS Severity Score (MSSS).
All MS patients within the registry identified to be of MENA origin ( = 192), and age- and sex-matched EUR-MS patients were included. Mean age was 42.9 years, 67% female. A total of 25% and 24% of EUR-MS and MENA-MS had progressive disease, with similar mean disease durations (11.5 and 11.4 years, respectively). Clinical and radiological disease activity (ARR, proportion with new/enlarging MRI lesions) was similar. MENA-MS showed greater disability progression over time (EDSS change = 0.24 vs. 0.06, = 0.01), a higher MSSS (3.12 vs. 2.67, = 0.04), and higher PI (0.34 vs. 0.27, = 0.07).
MENA-MS patients demonstrate higher disease severity compared to EUR-MS patients, despite having similar inflammatory measures of disease activity, with disability progression in the absence of relapses. These observations illustrate the importance of the intersections of environmental, socioeconomic, and genetic determinants in optimizing individualized MS care.
多发性硬化症(MS)在传统低负担地区(包括中东和北非地区)的发病率正在上升。
我们的目的是评估中东和北非地区(MENA)血统的多发性硬化症患者(MENA-MS)的疾病特征。
通过加拿大多伦多圣迈克尔医院的 MS 诊所登记处,确定了 MENA-MS 患者和年龄及性别匹配的欧洲血统多发性硬化症患者(EUR-MS)。通过每年复发率(ARR)、磁共振成像(MRI)活动、扩展残疾状况量表(EDSS)变化、进展指数(PI)和多发性硬化症严重程度评分(MSSS)来评估疾病活动和严重程度。
在登记处中确定为 MENA 血统的所有 MS 患者( = 192),并纳入了年龄和性别匹配的 EUR-MS 患者。平均年龄为 42.9 岁,女性占 67%。EUR-MS 和 MENA-MS 中分别有 25%和 24%的患者患有进展性疾病,平均疾病持续时间相似(分别为 11.5 和 11.4 年)。临床和放射学疾病活动(ARR,新/扩大 MRI 病变的比例)相似。MENA-MS 随时间推移显示出更大的残疾进展(EDSS 变化 = 0.24 对 0.06, = 0.01),更高的 MSSS(3.12 对 2.67, = 0.04)和更高的 PI(0.34 对 0.27, = 0.07)。
尽管 MENA-MS 患者的疾病活动炎症指标相似,但与 EUR-MS 患者相比,他们的疾病严重程度更高,且在没有复发的情况下残疾进展。这些观察结果说明了环境、社会经济和遗传决定因素相互作用在优化个体化多发性硬化症护理中的重要性。